| Identification | Back Directory | [Name]
1H-Pyrazole-4-carboxamide, 3-[2-(1-cyclopropyl-4,6-difluoro-1H-benzimidazol-5-yl)ethynyl]-1-[(3S,5R)-5-(methoxymethyl)-1-(1-oxo-2-propen-1-yl)-3-pyrrolidinyl]-5-(methylamino)- | [CAS]
2750709-91-0 | [Synonyms]
Resigratinib (KIN-3248)
1H-Pyrazole-4-carboxamide, 3-[2-(1-cyclopropyl-4,6-difluoro-1H-benzimidazol-5-yl)ethynyl]-1-[(3S,5R)-5-(methoxymethyl)-1-(1-oxo-2-propen-1-yl)-3-pyrrolidinyl]-5-(methylamino)- | [Molecular Formula]
C26H27F2N7O3 | [MOL File]
2750709-91-0.mol | [Molecular Weight]
523.53 |
| Chemical Properties | Back Directory | [Boiling point ]
782.4±70.0 °C(Predicted) | [density ]
1.47±0.1 g/cm3(Predicted) | [form ]
Solid | [pka]
14.85±0.50(Predicted) | [color ]
White to off-white | [InChIKey]
YXVDEILMUVTDMK-JKSUJKDBSA-N | [SMILES]
N1([C@H]2C[C@H](COC)N(C(=O)C=C)C2)C(NC)=C(C(N)=O)C(C#CC2=C(F)C=C3N(C4CC4)C=NC3=C2F)=N1 |
| Hazard Information | Back Directory | [Uses]
Resigratinib (KIN-3248) is a FGFR tyrosine kinase inhibitor, with antineoplastic effect[1]. | [References]
[1] Franovic, et al. Treatment of cancer with an FGFR kinase inhibitor. World Intellectual Property Organization, WO2023107979 A1 2023-06-15. |
|
|